Strategies to reduce the risks of mRNA drug and vaccine toxicity.
Level 5 - mechanism / opinion, no new human data
Narrative review synthesizing mechanisms of toxicity and risk-reduction strategies without original empirical data or systematic search protocol.
PubMed 38263456 · doi:10.1038/s41573-023-00859-3
What was done
This narrative review synthesized mechanistic and translational literature on toxicity concerns associated with mRNA therapeutics and vaccines formulated with lipid nanoparticles (LNPs). The authors evaluated how structural components, manufacturing methods, delivery routes, and expressed proteins contribute to reactogenicity and tissue-specific toxicity across vaccines, protein replacement therapies, and gene editing platforms. Screening tools, including in vivo and advanced in vitro models, were also evaluated for their utility in detecting off-target risks.
What was found
The abstract presents a qualitative conceptual review and reports no quantitative findings or effect sizes. Key focus areas identified include the influence of cell tropism, tissue distribution, and common biochemical and cellular pathways on adverse event profiles across clinical applications.
Why it matters
As mRNA-LNP technology expands beyond infectious disease vaccines into chronic indications like gene editing and protein replacement, identifying the drivers of toxicity and improving preclinical safety screening models are necessary steps for clinical translation.
Limits
The paper is a non-systematic review that introduces no primary human clinical data or meta-analytic pooling. Comparative safety tradeoffs between different LNP formulations or administration routes are discussed theoretically without reporting systematic performance metrics.
Cited by
- supports Over one billion people worldwide have been injected with lipid nanoparticles (LNPs), which are used to deliver mRNA vaccines.